A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. (Q35162749)

6 August 2017

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. (English)

1 reference

amyotrophic lateral sclerosis

6 August 2017

1 reference

14

Hiroshi Mitsumoto

1 reference

6 August 2017

21

Michael Graves

1 reference

6 August 2017

19

Leo F McCluskey

1 reference

6 August 2017

Paul H Gordon

1

1 reference

6 August 2017

Ying-Kuen Cheung

2

1 reference

6 August 2017

Bruce Levin

3

1 reference

6 August 2017

Howard Andrews

4

1 reference

6 August 2017

Carolyn Doorish

5

1 reference

6 August 2017

Robert B Macarthur

6

1 reference

6 August 2017

Jacqueline Montes

7

1 reference

6 August 2017

Kate Bednarz

8

1 reference

6 August 2017

Julaine Florence

9

1 reference

6 August 2017

Julie Rowin

10

1 reference

6 August 2017

Kevin Boylan

11

1 reference

6 August 2017

Tahseen Mozaffar

12

1 reference

6 August 2017

Rup Tandan

13

1 reference

6 August 2017

Elizabeth A Kelvin

15

1 reference

6 August 2017

John Chapin

16

1 reference

6 August 2017

Richard Bedlack

17

1 reference

6 August 2017

Michael Rivner

18

1 reference

6 August 2017

Alan Pestronk

20

1 reference

6 August 2017

Eric J Sorenson

22

1 reference

6 August 2017

Richard J Barohn

23

1 reference

6 August 2017

Jerry M Belsh

24

1 reference

6 August 2017

Jau-Shin Lou

25

1 reference

6 August 2017

Todd Levine

26

1 reference

6 August 2017

David Saperstein

27

1 reference

6 August 2017

Robert G Miller

28

1 reference

6 August 2017

Stephen N Scelsa

29

1 reference

6 August 2017

Combination Drug Selection Trial Study Group

30

1 reference

6 August 2017

1 August 2008

1 reference

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

6 August 2017

1 reference

6 August 2017

9

1 reference

6 August 2017

4

1 reference

6 August 2017

212-222

1 reference

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Phase II/III randomized trial of TCH346 in patients with ALS

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Selecting promising ALS therapies in clinical trials.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

A clinical trial of creatine in ALS.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Mitochondrial involvement in amyotrophic lateral sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Amyotrophic lateral sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Clinical pharmacokinetics of doxycycline and minocycline

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354803

Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.

13 July 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Minocycline delays disease onset and mortality in a transgenic model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

21 January 2018

The utility of futility.

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

The ALSFRSr predicts survival time in an ALS clinic population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Outcome measures for early phase clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

The Timed Up and Go test: Predicting falls in ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17482960802195632

A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)

21 January 2018

1 reference

12 December 2020

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

12 December 2020

The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group

1 reference

12 December 2020

Quality of life in ALS is maintained as physical function declines

1 reference

12 December 2020

Trial of celecoxib in amyotrophic lateral sclerosis

1 reference

12 December 2020

Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis

1 reference

12 December 2020

Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis

1 reference

12 December 2020

10.1080/17482960802195632

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference